PharmiWeb Recruiter Blog

• Wednesday 21st June 2023
• 16:00 BST - 11:00 EST - 08:00 PST
• Free to Join

Are you looking to improve your organisation’s Diversity, Equity, and Inclusion strategy? Do you want to learn best practices from one of the world’s leading clinical research organisations?

In an era characterised by rapid advancements in science and technology, the influence of younger generations cannot be overlooked. As life science recruiters, it’s crucial to understand and address the top societal concerns of Gen Z and millennial jobseekers in order to attract and retain top talent in 2023 and beyond.

Chicago, IL (May 25, 2023) — Advanced Clinical, a privately held clinical research services organization committed to providing a better clinical experience across the drug development journey, is pleased to announce a biopharmaceutical industry-first collaboration with StuffThatWorks, the first data-driven community platform that uses crowdsourcing and AI to transform patient journeys and health metrics into actionable real world data in an effort to streamline research and bring clinical research closer to patients and caregivers.

Company receives highest average rating across all 26 performance attributes out of 34 CROs included in survey and highest Net Promoter Score demonstrating likelihood to be recommended to colleagues

DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been rated the “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey. Among the 34 CROs included in the survey, Parexel received the highest average rating across all 26 performance attributes evaluated.

Basel, Switzerland, May 31, 2023 – The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.

• Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global net sales.
• Life Edit has the option to a global profit share on one programme.
• Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent company, as part of ElevateBio’s 401 million US dollars Series D financing.

Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets.

• Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines.
• Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London.
• Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines.
• Expansion follows recent acceptance of a Drug Master File and first investigational new drug application using doggybone DNA.

Hampton, UK, 24 May 2023 – Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames.

• Global biopharmaceutical services provider Allucent has partnered with THREAD, an innovative decentralized clinical trial (DCT) and eCOA technology provider, to launch Allucent Patient Direct Trials, a DCT offering focused on small and mid-sized biotech companies.
• Allucent Patient Direct Trials provides small and mid-sized biotech companies with access to advanced technologies, operational experience, and regulatory expertise to design and execute more patient-focused trials and realize the efficiencies of a DCT approach.
• The announcement coincides with the 2023 World Orphan Drug Congress, where Allucent will lead a panel session on the value of decentralized study designs and protocol optimization, especially for rare disease therapeutic development. 

CARY, N.C., May 23, 2023 – Global biopharmaceutical services provider Allucent announced today that it has partnered with THREAD, an innovative DCT and eCOA technology provider, to launch Allucent Patient Direct Trials. The new offering brings advanced technologies and development and regulatory expertise to small and emerging biotechnology companies to support them in designing and overseeing customized decentralized clinical trial approaches that address their needs.

In the context of recruitment, EVP stands for Employee Value Proposition. It refers to the unique set of benefits, rewards, and opportunities that an employer offers to its employees in exchange for their skills, knowledge, and contributions to the organisation.

• The Oxford-based company has relocated to the landmark Seacourt Tower in Botley, upgrading its office space to accommodate its growing team of AI specialists

OXFORD, UK, 15 May 2023 – Brainomix, the AI-powered medtech solutions company, today announced it has moved to a new head office in Oxford, located in the landmark Seacourt Tower in Botley.